Bowman-Birk inhibitor concentrate: A novel therapeutic agent for patients with active ulcerative colitis

Digestive Diseases and Sciences

Volumn 53, Issue 1, 2008, Pages 175-180

  Lichtenstein, Gary R ^a   Deren, Julius J ^a   Katz, Seymour ^a   Lewis, James D ^a   Kennedy, Ann R ^a   Ware, Jeffrey H ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Colitis; Inflammatory bowel disease; Protease inhibitor; Safety; Toxicity

Indexed keywords

BOWMAN BIRK INHIBITOR; CORTICOSTEROID; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFECATION; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; DRUG SAFETY; FEMALE; FLATULENCE; HUMAN; MALE; NAUSEA AND VOMITING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; REMISSION; SCORING SYSTEM; SIDE EFFECT; SUTHERLAND DISEASE ACTIVITY INDEX; THERAPY EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; ULCERATIVE COLITIS;

COLITIS, ULCERATIVE; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; HUMANS; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TRYPSIN INHIBITOR, BOWMAN-BIRK SOYBEAN; TRYPSIN INHIBITORS;

EID: 37249027703     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-007-9840-2     Document Type: Article

References (25)

1. Solomon MJ, Schnitzler M (1998) Cancer and inflammatory bowel disease: bias, epidemiology, surveillance, and treatment. World J Surg 22:352-358
2. Dayal Y, DeLellis RA (1989) The gastrointestinal tract. In: Cotran RS, Kumar V, Robbins SL (eds) Robbins pathologic basis of disease. Saunders, Philadelphia, pp 827-910
3. Senda S, Fujiyama Y, Bamba T, Hosoda S (1993) Treatment of ulcerative colitis with camostat mesilate, a serine protease inhibitor. Intern Med 32:350-354
4. Armstrong WB, Kennedy AR, Wan XS, Taylor TH, Nguyen QA, Jensen J, Thompson W, Lagerberg W, Meyskens FL Jr (2000) Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a phase IIa chemoprevention trial. Clin Cancer Res 6:4684-4691
5. Armstrong WB, Kennedy AR, Wan XS, Atiba J, McLaren CE, Meyskens FL Jr (2000) Single-dose administration of Bowman-Birk inhibitor concentrate in patients with oral leukoplakia. Cancer Epidemiol Biomarkers Prev 9:43-47
6. Meyskens FL, Armstrong WB, Wan XS, Taylor TH, Jenson J, Thompson W, Nguyen QA, Kennedy AR (1999) Bowman-Birk inhibitor concentrate (BBIC) affects oral leukoplakia lesion size, neu protein levels and proteolytic activity in buccal mucosal cells. Proc Am Assoc Cancer Res 40:Abstract #2855
7. Malkowicz SB, McKenna WG, Vaughn DJ, Wan XS, Propert KJ, Rockwell K, Marks SHF, Wein AJ, Kennedy AR (2001) Effects of Bowman-Birk inhibitor concentrate (BBIC) in patients with benign prostatic hyperplasia. Prostate 48:16-28
8. Kennedy AR (1998) Chemopreventive agents: protease inhibitors. Pharmacol Ther 78:167-209
9. Billings PC, Newberne P, Kennedy AR (1990) Protease inhibitor suppression of colon and anal gland carcinogenesis induced by dimethylhydrazine. Carcinogenesis 11:1083-1086
10. Ware JH, Wan XS, Newberne P, Kennedy AR (1999) Bowman-Birk inhibitor concentrate reduces colon inflammation in mice with dextran sulfate sodium-induced ulcerative colitis. Dig Dis Sci 44:896-890
11. Hawkins JV, Emmel EL, Feuer JJ, Nedelman MA, Harvey CJ, Klein HJ, Rozmiarek J, Kennedy AR, Lichtenstein GR, Billings PC (1996) Protease activity in a hapten-induced model of ulcerative colitis in rats. Dig Dis Sci 42:1969-1980
12. Tikhonova TV, Gladysheva IP, Kazanshaya NF, Larionova NI (1994) Hydrolysis of elastin by human leukocyte elastase and cathepsin G: inhibition by Bowman Birk type inhibitor. Biochemistry (Moscow) 59:1295-1299
13. Larionova NI, Gladysheva IP, Tikhonova TV, Kazanskaia NF (1993) Inhibition of cathepsin G and elastase from human granulocytes by multiple forms of the Bowman-Birk type of soy inhibitor. Biochemistry (Moscow) 58:1437-1444
14. Gladysheva IP, Larionova NI, Gladyshev DP, Tikhonova TV, Kazanskaia NF (1994) The classical Bowman-Birk soy inhibitor is an effective inhibitor of human granulocyte alpha-chymotrypsin and cathepsin G. Biochemistry (Moscow) 59(4):513-518
15. Ware JH, Wan XS, Rubin H, Schechter NM, Kennedy AR (1997) Soybean Bowman-Birk protease inhibitor is a highly effective inhibitor of human mast cell chymase. Arch Biochem Biophys 344:133-138
16. Sutherland LR, Martin F, Greer S, Robinson M, Greenberger N, Saibil F, Martin T, Sparr J, Prokipchuk E, Borgen L (1987) 5-aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 92:1894-1898
17. Kennedy AR, Szuhaj BF, Newberne PM, Billings PC (1993) Preparation and production of a cancer chemopreventive agent, Bowman-Birk inhibitor concentrate. Nutr Cancer 19:281-302
18. Lewis JD, Lichtenstein GR, Stein RB, Deren JJ, Judge TA, Fogt F, Furth EE, Demissie EJ, Hurd LB, Su CG, Keilbaugh SA, Lazar MA, Wu GD (2001) An open-label trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitis. Am J Gastroenterol 96:3323-3328
19. Mahadevan U, Tremaine WJ, Johnson T, Pike MG, Mays DC, Lipsky JJ, Sandborn WJ (2000) Intravenous azathioprine in severe ulcerative colitis: a pilot study. Am J Gastroenterol 95:3463-3468
20. Safdi M, DeMicco M, Sninsky C, Banks P, Wruble L, Deren JJ, Koval G, Nichols T, Targan S, Fleishman C, Wiita B (1997) A double-blind comparison of oral versus rectal mesalamine versus combination therapy in treatment of distal ulcerative colitis. Am J Gastroenterol 92:1867-1871
21. Sandborn WJ, Tremaine WJ, Schroeder KW, Steiner BL, Batts KP, Lawson GM (1993) Cyclosporine enemas for treatment-resistant, mildly to moderately active, left-sided ulcerative colitis. Am J Gastroenterol 88:640-645
22. Billings PC, Clair WHS, Maki PA, Kennedy AR (1992) Distribution of the Bowman-Birk inhibitor in mice following oral administration. Cancer Lett 62:191-197
23. Yavelow J, Finlay TH, Kennedy AR, Troll W (1983) Bowman-Birk soybean protease inhibitor as an anticarcinogen. Cancer Res 43:2454-2459
24. Billings PC, Brandon DL, Habres JM (1991) Internalization of the Bowman-Birk protease inhibitor by intestinal epithelial cells. Eur J Cancer 27:903-908
25. Persiani S, Yeung A, Shen WC, Kennedy AR (1991) Polylysine conjugates of Bowman-Birk protease inhibitor as targeted anticarcinogenic agents. Carcinogenesis 12:1149-1152